Mary-Beth Fennell Plum, PharmD

Low-intensity warfarin (target international normalized ratio [INR], 1.5–2.0) effectively prevents recurrent venous thromboembolism without increasing the risk of major bleeding when used long-term for secondary prophylaxis. This is a reasonable approach following at least 3 to 12 months of full-intensity warfarin after the initial thromboembolic event.

Low-intensity warfarin (target international normalized ratio [INR], 1.5–2.0) effectively prevents recurrent venous thromboembolism without increasing the risk of major bleeding when used long-term for secondary prophylaxis. This is a reasonable approach following at least 3 to 12 months of full-intensity warfarin after the initial thromboembolic event.

Low-intensity warfarin (target international normalized ratio [INR], 1.5–2.0) effectively prevents recurrent venous thromboembolism without increasing the risk of major bleeding when used long-term for secondary prophylaxis. This is a reasonable approach following at least 3 to 12 months of full-intensity warfarin after the initial thromboembolic event.